The chairman of Cambridge Therapeutics in Teaneck, New Jersey, John Klein has obtained FDA approval for more than 300 generic drugs in the course of his 30-year career. His work at Cambridge Therapeutics has resulted in honors including high ranking on Forbes’ list of the Top 100 CEOs. Complementing that work, John Klein closely follows health and related developments in New Jersey. The state’s attorney general, Gurbir Grewal, recently announced new efforts aimed at battling the state’s opioid epidemic. Grewal has proposed a rule change to make medication-assisted treatment, long recognized as the most effective way to treat opioid addiction, more widely available to the state’s residents through use of telemedicine technology. Allowing physicians to assess and prescribe treatments to patients through two-way, real-time video communication will ensure more people can access medication-assisted treatment and improve their odds of surviving their opioid addiction. In addition, Grewa
Based in New Jersey, John Klein guides Cambridge Therapeutics as the company offers innovative pharmaceutical industry solutions that improve patient compliance and outcomes. John Klein and his Cambridge Therapeutics team provide a combination of processing software and point-of-care prescription dispensing solutions that enable pharmacies, urgent care centers, hospitals, and private practice physicians to deliver optimal care.